Neratinib

From Self-sufficiency
Jump to: navigation, search
Neratinib
File:Neratinib skeletal.svg
Systematic (IUPAC) name
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
Clinical data
Routes of
administration		 Oral
Identifiers
CAS Number 698387-09-6
ATC code none
PubChem CID 9915743
Chemical data
Formula C30H29ClN6O3
Molar mass 557.04 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Neratinib (HKI-272) is a tyrosine kinase inhibitor[1][2] under investigation for the treatment breast cancer[3] and other solid tumours.

Like lapatinib and BIBW 2992, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.[4]

Clinical trials

It will be included in the forthcoming I-SPY2 breast cancer trial.[5]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine kinase inhibitors ("-nib")
Other


Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
  1. ↑ "Definition of neratinib - National Cancer Institute Drug Dictionary". Retrieved 2008-12-01. 
  2. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. ↑ ClinicalTrials.gov NCT00398567 A Phase 1/2 Study Of HKI-272 In Combination With Herceptin In Subjects With Advanced Breast Cancer
  4. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. ↑ http://www.reuters.com/article/idUSN1612347120100317 "Breast cancer study aims to speed drugs, cooperation" March 2010
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Neratinib&oldid=23700"